Patients on dialysis who take denosumab face a 36% higher risk for major cardiovascular adverse events than patients who take oral bisphosphonates, according to a study published Jan. 6 in Annals of Internal Medicine.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
